8891
document
Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis . BACKGROUND We previously reported urinary podocytes to be a marker of glomerular injury . The aim of the present study was to determine whether cerivastatin , a newly developed , potent synthetic statin , affects proteinuria and urinary podocyte excretion in patients with chronic glomerulonephritis ( CGN ) . METHODS We randomly assigned 40 normotensive hypercholesterolemic patients with CGN to receive either cerivastatin 0.15 mg/day ( n=20 ) or placebo ( n=20 ) . Subjects comprised 24 men and 16 women , with a mean age of 40.8+/-14.4 years ; 27 had IgA nephropathy and 13 had non-IgA proliferative glomerulonephritis . Treatment was continued for 6 months . Plasma total cholesterol , HDL-cholesterol , LDL-cholesterol and triglycerides , urinary protein excretion and the number of podocytes were measured before treatment and at 3 and 6 months after treatment . RESULTS After 6 months , a significant reduction in total cholesterol ( P < 0.001 ) , LDL-cholesterol ( P < 0.001 ) and triglycerides ( P < 0.05 ) , and a significant increase in HDL-cholesterol ( P < 0.001 ) were observed in the group treated with cerivastatin . Urinary protein excretion decreased from 1.8+/-0.6 to 0.8+/-0.4 g/day , ( P < 0.01 ) in this group , and urinary podocyte excretion decreased from 1.6+/-0.6 to 0.9+/-0.4 cells/ml ( P < 0.01 ) . However , placebo showed little effect on these lipid levels , urinary protein excretion and urinary podocyte excretion . The differences between the cerivastatin group and the placebo group were significant ( cholesterol , P < 0.001 ; LDL-cholesterol , P < 0.001 ; triglycerides , P < 0.05 ; HDL-cholesterol , P < 0.001 ; urinary protein , P < 0.01 ; and urinary podocytes , P < 0.01 ) . CONCLUSION Statins such as cerivastatin may be beneficial for restoration of injured podocytes in patients with CGN and hypercholesterolaemia .
8892
Intervention_Pharmacological
cerivastatin
8893
Intervention_Pharmacological
cerivastatin
8894
Intervention_Pharmacological
cerivastatin
8895
Intervention_Control
placebo
8896
Intervention_Pharmacological
cerivastatin
8897
Intervention_Control
placebo
8898
Outcome_Physical
Plasma total cholesterol
8899
Outcome_Physical
HDL-cholesterol
8900
Outcome_Physical
LDL-cholesterol and triglycerides
8901
Outcome_Physical
urinary protein excretion
8902
Outcome_Physical
number of podocytes
8903
Outcome_Physical
total cholesterol
8904
Outcome_Physical
LDL-cholesterol
8905
Outcome_Physical
triglycerides
8906
Outcome_Physical
increase in HDL-cholesterol
8907
Outcome_Physical
Urinary protein excretion
8908
Outcome_Physical
urinary podocyte excretion
8909
Outcome_Physical
lipid levels
8910
Outcome_Physical
urinary protein excretion
8911
Outcome_Physical
urinary podocyte excretion
8912
Outcome_Physical
LDL-cholesterol
8913
Outcome_Physical
triglycerides
8914
Outcome_Physical
HDL-cholesterol
8915
Outcome_Physical
urinary protein
8916
Outcome_Physical
urinary podocytes
8917
Participant_Condition
chronic glomerulonephritis .
8918
Participant_Condition
chronic glomerulonephritis ( CGN )
8919
Participant_Sample-size
40
8920
Participant_Condition
hypercholesterolemic
8921
Participant_Condition
CGN
8922
Participant_Sample-size
24
8923
Participant_Sex
men
8924
Participant_Sample-size
16
8925
Participant_Sex
women
8926
Participant_Age
40.8+/-14.4
8927
Participant_Sample-size
27
8928
Participant_Condition
IgA nephropathy
8929
Participant_Sample-size
13
8930
Participant_Condition
non-IgA proliferative glomerulonephritis
8931
Participant_Condition
CGN
8932
Participant_Condition
hypercholesterolaemia